

# ISCP



International Society of Cardiovascular Pharmacotherapy

## PRELIMINARY PROGRAMME

### XVII INTERNATIONAL CONGRESS OF THE ISCP BUCHAREST – ROMANIA – 4<sup>th</sup> – 5<sup>th</sup> MAY 2012

**4th MAY 2012**

#### **Session 1. CARDIOVASCULAR DISEASE PREVENTION**

Chair: Jay Cohn (USA) and John McNeil (AUS)

Statins in primary prevention - An ongoing controversy. *Kausik Ray (UK)*

Aspirin in primary prevention - A Paradigm change. *Rao Khondapally (UK)*

Panel Discussion. *Kausik Ray (UK), Rao Khondapally (UK), Jay Cohn (USA), John McNeil (AUS)*

#### **Session 2. HDL in ATHEROGENESIS AND DISEASE PROGRESSION – Role of CETP inhibition in management**

Chair: Thomas Luscher (CH) and Juan Carlos Kaski (UK)

HDL - not just a transport system - pleiotropic functions of high-density lipoproteins. *Gillian Cockerill (UK)*

Raising HDL through CETP inhibition – the way forward? *Anthony Wierzbicki (UK)*

Why targeting HDL to improve vascular function? *Lina Badimon (ESP)*

Do CETP inhibitors increase cardiovascular risk? *Thomas Luscher (CH)*

#### **Session 3. MANAGEMENT OF HYPERTENSION: a glimpse beyond guidelines**

Chair: Dan Dominic Ionescu (RO) and Vladimir Popov (RUS)

Hypertension guidelines: concordances, discordances and expectations. *Renata Cifkova (CZ)*

Antihypertensive effectiveness: blood pressure or target organ protection. *Thomas Kahan (S)*

Pathogenesis: Renin, angiotensin and aldosterone- team players or soloists? *Felipe Martinez (RA)*

Novel pharmacological approaches in hypertension. *Faiez Zannad (F)*

# ISCP



International Society of Cardiovascular Pharmacotherapy

**5th MAY 2012**

## **Session 1. MANAGEMENT OF ACS – Role of antiplatelet drugs. – Guidelines and beyond**

Chair: Peter Clemmensen (DK) and Albert Ferro (UK)

Antiplatelet therapy in ACS - Current European and American guidelines: A critical appraisal. *Pablo Avanzas (ESP)*

New vs "old" antiplatelet agents:

- The platelet expert view; *Albert Ferro (UK)*
- The managing cardiologist's view; *Peter Clemmensen (DK)*
- The interventionist's view. *Nicolas Danchin (F)*

## **Session 2. THROMBOSIS FORUM: controversies in antithrombotic therapy**

Chair: G. Andrei Dan(RO) and Antonio Bayes de Luna (ESP)

Antiplatelets and anticoagulant treatment in atrial fibrillation

- Anti factor Xa better than antithrombin PRO. *Ali Oto (TR)*
- Anti factor Xa better than antithrombin CONS. *Antonio Martinez Rubio (ESP)*
- Warfarin: an obsolete treatment in clinical practice? PRO. *Bela Merkely (H)*
- Warfarin: an obsolete treatment in clinical practice? CONS. *TBC*

## **Session 3. NEUFELD LECTURE**

Chair: Juan Carlos Kaski (UK) and G. Andrei Dan(RO)

Pharmacogenomics: Ready for use in clinical practice? *Munir Pirmohamed (UK)*

## **Session 4. HEART FAILURE**

Chair: Dimitrios Tziakas (GR) and TBC

Pharmacological therapy of HF in 2012: what we know and what are we looking for. *Piotr Ponikowski (PL)*

Biomarkers as tool to monitor therapy in HF. *Robert Hatala (SK)*

Pharmacological therapy for HF – What's new? *Stefan D. Anker (DE)*

**5 sponsored Symposia – TBC**